Literature DB >> 22874515

Tenofovir-associated proteinuria.

Mark D Kelly1, Abby Gibson, Harry Bartlett, Diane Rowling, John Patten.   

Abstract

Proteinuria was observed in 27% of 153 patients taking tenofovir for more than 1 year. Concomitant protease inhibitor therapy and cumulative tenofovir exposure were independently associated with proteinuria in this cohort. Proteinuria was reversible in 11 of 12 patients who ceased tenofovir because of proteinuria without altering other medications. Clinicians should be aware that tenofovir can cause reversible proteinuria in patients with HIV.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22874515     DOI: 10.1097/QAD.0b013e32835883bf

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  4 in total

1.  Tenofovir treatment duration predicts proteinuria in a multiethnic United States Cohort of children and adolescents with perinatal HIV-1 infection.

Authors:  Murli Purswani; Kunjal Patel; Jeffrey B Kopp; George R Seage; Miriam C Chernoff; Rohan Hazra; George K Siberry; Lynne M Mofenson; Gwendolyn B Scott; Russell B Van Dyke
Journal:  Pediatr Infect Dis J       Date:  2013-05       Impact factor: 2.129

2.  Co-morbidity, ageing and predicted mortality in antiretroviral treated Australian men: a quantitative analysis.

Authors:  Luis Furuya-Kanamori; Mark D Kelly; Samantha J McKenzie
Journal:  PLoS One       Date:  2013-10-25       Impact factor: 3.240

3.  Long-Term Follow-Up of Proteinuria and Estimated Glomerular Filtration Rate in HIV-Infected Patients with Tubular Proteinuria.

Authors:  Hélène Peyriere; Amandine Cournil; Marie-Laure Casanova; Stéphanie Badiou; Jean-Paul Cristol; Jacques Reynes
Journal:  PLoS One       Date:  2015-11-16       Impact factor: 3.240

Review 4.  The role of drug transporters in the kidney: lessons from tenofovir.

Authors:  Darren M Moss; Megan Neary; Andrew Owen
Journal:  Front Pharmacol       Date:  2014-11-11       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.